FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 240 filers reported holding FATE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $217,713 | -7.6% | 45,738 | +10.7% | 0.24% | -17.0% |
Q1 2023 | $235,507 | +26.5% | 41,317 | +123.9% | 0.29% | +58.8% |
Q4 2022 | $186,231 | -54.4% | 18,457 | -9.0% | 0.18% | -55.2% |
Q3 2022 | $408,000 | -0.5% | 20,273 | +22.7% | 0.41% | +7.1% |
Q2 2022 | $410,000 | -43.9% | 16,526 | -12.3% | 0.38% | -28.8% |
Q1 2022 | $731,000 | +22.4% | 18,849 | +84.8% | 0.53% | +29.1% |
Q4 2021 | $597,000 | -79.5% | 10,200 | -68.1% | 0.41% | -42.4% |
Q4 2020 | $2,910,000 | – | 32,000 | – | 0.72% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |